Experience

Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule…

Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering…

Davis Polk advised the joint lead managers in connection with the debut offering of $300 million 2.125% bonds due 2025 issued by New Oriental Education & Technology Group Inc. New…

Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary Shares. Each ADS represents five ordinary shares. Genetron has…

Davis Polk advised the initial purchasers on the Regulation S offering of high-yield notes by Ronshine China Holdings Limited of $250 million principal amount of 7.350% senior notes due…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $200 million 8.300% senior notes due 2023. Zhenro Properties Group…

Davis Polk advised the underwriters in the secondary listing and initial public offering of NetEase, Inc. on the Hong Kong Stock Exchange. The gross proceeds from the global offering…

Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend Biotech Corporation of 21,188,750 American Depositary Shares, each…

Davis Polk advised the arrangers in connection with the establishment of the $2 billion medium-term note program of Coastal Emerald Limited, which is an indirectly wholly owned subsidiary…

Davis Polk advised Hongkong Ideal Investment Limited Beijing (the “Issuer”) on its $55 million Regulation S offering of 14.750% guaranteed senior notes due 2022, to be consolidated and form…